Wei L, et al. -In Asian participants with genotype 1 or 4 chronic hepatitis C infection registered in the elbasvir/grazoprevir phase 2/3 clinical trials, researchers evaluated the effectiveness and safety of elbasvir/grazoprevir. In this integrated analysis of data from 12 international phase 2/3 clinical trials, 780 Asian participants from 15 countries were involved. This analysis included participants who received elbasvir 50 mg/grazoprevir 100 mg once daily for 12 weeks or elbasvir/grazoprevir plus ribavirin for 16 weeks. For Asian people with hepatitis C virus GT1b infection, 12 weeks of elbasvir/grazoprevir was an efficacious and well-tolerated treatment option. Nasopharyngitis, upper respiratory tract infection and diarrhea were the most frequently reported adverse events.